Trials / Completed
CompletedNCT03692676
Characteristics of Pts Initiating Spiriva Respimat in Asthma
Characteristics of Patients Initiating Spiriva Respimat in Asthma in the UK: a Cross-sectional Study Based on the Clinical Practice Research Datalink
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 116,133 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a cross-sectional, non-interventional study based on existing data (NISed).
Detailed description
The UK CPRD data will be used to assess the characteristics of asthma patients who were prescribed ICS/LABA FDC before the index date and who initiated Spiriva Respimat, or received a higher dose of ICS/LABA FDC, or initiated LTRA, or switched to a new ICS/LABA FDC in the UK during the study period (September 2014-December 2017) enabling to assess potential channeling of prescribing to different patient populations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Spiriva Respimat | soft-mist inhaler |
Timeline
- Start date
- 2019-03-05
- Primary completion
- 2019-10-11
- Completion
- 2019-10-11
- First posted
- 2018-10-02
- Last updated
- 2025-04-17
- Results posted
- 2020-12-21
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03692676. Inclusion in this directory is not an endorsement.